Topic - Biontech

Related Stories



“To date, there is no evidence that an adaptation of BioNTech’s current COVID-19 vaccine against key identified emerging variants is necessary,” the company said in detailing first-quarter results.

Pfizer partner BioNTech is exploring a variant-specific vaccine strategy →

© Copyright 2021 The Washington Times, LLC
3600 New York Avenue NE, Washington, DC 20002

Switch to Desktop version